STAT+: Humana CEO Bruce Broussard to step down next year
Bruce Broussard, CEO of health insurance giant Humana, will step down next year after leading…
Category: Medicine
STAT+: Medicare may plan to negotiate drug prices, but some states are taking their own steps to lower costs
Anticipation may be high that Medicare can wring lower prices out of drugmakers, but a…
STAT+: European regulators consider appeal over Amylyx ALS drug
LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially…
In major test for eGenesis, gene-edited pig kidneys kept monkeys alive for more than two years
Scientists at a Massachusetts-based biotechnology company and their academic research partners reported Wednesday that an…
With Ozempic, Wall Street moves on from a whole other class of medicines
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
Major biomedical research funder Wellcome Trust names Røttingen as its new CEO
LONDON — The Wellcome Trust — the world’s second largest private funder of biomedical research…
Chronic kidney disease raises risk of sudden cardiac arrest among Hispanics and Latinos
Chronic kidney disease was the strongest risk factor for sudden cardiac arrest among Hispanic and…
The ‘abortion queen’ wants patients to have ‘skin in the game.’ Is that restricting access?
BRISTOL, Va. — Stephanie Rosenwinge was excited to work for the queen of abortion. She’d…
Opinion: The Wegovy shortage is part of a much bigger problem with weight loss drugs
After physically debilitating cancer treatment, Laurie Brunner encountered another medical hurdle: She had developed lymphedema…
Opinion: How good are AI health technologies? We have no idea
AI has the ability to revolutionize human health. It is used to detect potentially cancerous lesions in…
‘What I’m most proud of’: Nick Jonas talks about managing diabetes, his career, and building community
LAS VEGAS – Nick Jonas is a global superstar behind electrifying earworms like “Jealous,” “Chains,”…
STAT+: ‘Like playing the lottery’: A mixed picture for laid-off life sciences workers in Massachusetts
Gina Calvanese got laid off from Jounce Therapeutics, a struggling Cambridge biotech, in April but…
STAT+: Bernie Sanders bashes nonprofit hospitals over their tax breaks
WASHINGTON — Hospitals get tax breaks that are worth far more than the value of…
Robert F. Kennedy is pitching centrism on health care, even on abortion
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your…
What’s next in the Kaiser Permanente strike
You’re reading the web edition of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: Dana-Farber CEO on Mass General split: Boston needed a dedicated cancer hospital
One of the first items on Laurie Glimcher’s agenda after becoming CEO of the renowned…
STAT+: Sana to lay off nearly a third of staff, de-prioritize a key program
Sana Biotechnology, a startup that just a couple years ago raised over $1 billion off…
STAT+: A fraught question for the children of Alzheimer’s: Is it coming for us?
My sister has a fantasy about our old age: She imagines that the seven siblings…
STAT+: How doctors and nurses shape Google’s AI, DEA extends telehealth flexibilities
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how tech…
To protect chickens from bird flu, researchers try to CRISPR in immunity
LONDON — In this case, it was neither the chicken nor the egg that came…
Want a biotech buyout? Target cancer
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024
Hello, everyone, and nice to see you again. We have returned from an extended weekend…
STAT+: Akero’s treatment for NASH falls short in cirrhosis study
Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for…
The ‘model-eat-model world’ of clinical AI: How predictive power becomes a pitfall
A growing number of AI tools are being used to predict everything from sepsis to…
Opinion: Connecticut’s comptroller explains his thinking about GLP-1s for state employees
This article is part of a partnership between First Opinion and Tradeoffs, a podcast exploring our…
With a rare immunodeficiency disease, a performer and patient advocate learned lessons the hard way
When asked where he’s from, Casey Warford often waffles. He was born in San Antonio,…
Stroke deaths, despite advances in prevention, are set to near 10 million globally by 2050
The number of stroke deaths worldwide is set to climb 50% to nearly 10 million…
STAT+: Bristol ‘take-under’ of Mirati is not so great for biotech, but company’s new cancer target has potential
Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics: A take-under deal feels meh…
STAT+: FDA rejects Alnylam’s heart disease treatment over insufficient data
The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart…
STAT+: Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies
Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect…
STAT+: A Q&A with the global head of Boehringer Ingelheim’s innovation unit
LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined…
STAT+: Venture capital firm General Catalyst wants to buy a health system
Venture firms, convinced they’re jumpstarting the world’s most helpful tech products, have struggled mightily to…
.jpg)
STAT+: Bristol Myers to buy cancer player Mirati for more than $4.8 billion
Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug…
Inflammation gets its own research center, thanks to Chan Zuckerberg Initiative
CHICAGO — At what point does inflammation, a key component of the body’s immune defense…
STAT+: Judge dismisses Novo Nordisk lawsuit over compounded versions of Ozempic and Wegovy
In a setback for Novo Nordisk, a U.S. judge dismissed its lawsuit accusing a compound…
STAT+: Long underappreciated, gamma-delta T cells may be key to colon cancer defense, study says
Within the linings of our guts, immune cells patrol like sentries on a castle wall….
NIH funds expanded access projects for ALS
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: How payer-participating trials could help transform clinical research on FDA-approved drugs
Earlier this year, Food and Drug Administration Commissioner Robert M. Califf proposed something radical: that…
Opinion: The next frontier in biomedicine: AI models of the human immune system
If the Covid-19 pandemic has shown us one thing, it is how little we really…
Access to new tools to combat RSV in babies likely to prove challenging
In a fall in which new tools to fight old diseases — updated Covid-19 vaccines,…
Medicare’s proposal on nursing home staff is ‘insanity,’ key expert says
Some of the country’s top Medicare experts aren’t sold on a new Biden administration plan…
What’s on tap at HLTH, the health care industry jamboree that kicks off this weekend
STAT’s Mohana Ravindranath and Annalisa Merelli will be at HLTH in Las Vegas and will…
STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug
The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following…
FDA expert panel endorses idea of removing a component from flu vaccine
The Food and Drug Administration’s expert vaccine advisory panel on Thursday unanimously endorsed the idea…
Listen: Is the Nobel committee evolving? Plus, preventing public health’s wiliest virus
Will we ever get an HIV vaccine? And is the oft-criticized institution that awards the…
STAT+: Neurocrine reports second late-stage trial success for congenital adrenal hyperplasia drug
SAN DIEGO — Neurocrine Biosciences, a biotech focused on treating rare neurological and endocrine diseases,…
STAT+: Telehealth claims data suggest service duplication, Roche app to evaluate MS symptom
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how tech…
The future of health care in the House
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your…